Imatinib Mesylate for Palliative Second-Line Treatment of Advanced Biliary Tract Cancer: A Bicentric Phase II Study

Publisher： Karger

E-ISSN： 2296-5262|34|8-9|469-470

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.8-9, 2011-08, pp. : 469-470

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers

By  

Oncology, Vol. 76, Iss. 4, 2009-02 ,pp. : 254-261

Karger

Access to resources Recommend Favorite

Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

By  

Oncology, Vol. 80, Iss. 3-4, 2011-07 ,pp. : 238-246

Karger

Access to resources Recommend Favorite

Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues

By  

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3290-3297

John Wiley & Sons Inc

Access to resources Recommend Favorite

Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)

By  

Oncology, Vol. 89, Iss. 2, 2015-03 ,pp. : 70-78

Karger

Access to resources Recommend Favorite

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 270-274

Karger

Access to resources Recommend Favorite